Philadelphia FIGHT (FIGHT) was founded as the Community-Based Research Initiative on AIDS. Clinicians at FIGHT continue to be involved in a number of studies. Below are a list of clinical research trials at FIGHT.
Y-HEP Health Center | Jonathan Lax Health Center
The following clinical trials are ongoing at the Lax Center and currently enrolling patients:
Studies of the Immunopathogenesis of Chronic and Emerging Viral Infections
Description: Sponsored by The Wistar Institute
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who are Successfully Treated With a Complicated Regimen
Trial Number: GS-US-621-6289
Description: An operationally seamless Phase 2/3 randomized, open-label, multicenter, active-controlled study to evaluate the safety and efficacy of bictregravir/lenacapavir versus stable baseline regimen in virologically suppressed people with HIV-1 on stable complex treatment regimens
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
Trial Number: GS-US-621-6290
Description: A phase 3 double-blind multicenter randomized active-controlled study to evaluate the safety and efficacy of bictegravir/lenacapavir versus Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide) in virologically suppressed people with HIV-1
PROs of a Tele-Derm Program
Description: An observational study examining patient-reported outcomes of an on-site tele-dermatology program among both patients living with HIV and patients identifying as LGBTQ+
The following clinical trials are ongoing at YHEP Youth Health Center but are NOT currently enrolling new patients:
Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir (LEN) for HIV Pre-Exposure Prophylaxis (PrEP)
Trial Number: GS-US-528-9023
Description: A Phase 3, Double-Blind, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of Subcutaneous Twice Yearly Long-Acting Lenacapavir for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Gender Non-binary People ≥ 16 Years of Age who Have Sex with Male Partners and are at Risk for HIV Infection
Acceptability of Long-Acting Injectable Lenacapavir (LEN) Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate (F/TDF) for HIV Pre-Exposure Prophylaxis (PrEP): Qualitative Insights Into Social and Behavioral Contexts
Trial Number: GS-US-528-6364
Description: A Qualitative Study for participants already enrolled in GS-US-528-9023 to examine Acceptability of Long-Acting Injectable Lenacapavir Versus Oral Emtricitabine/Tenofovir Disoproxil Fumarate for HIV Pre-Exposure Prophylaxis in Cisgender Men, Transgender Women, Transgender Men, and Nonbinary People
PennE
Description: Supporting PrEP Initiation and Mental Health Screening in Community Care Settings with Automated, Proactive Text-Messaging
For more information on any of the clinical trials listed, please contact the Research Department at 215-344-1631.